Transcatheter Tricuspid Valve Edge-to-Edge Repair in Cardiac Wild-Type Transthyretin Amyloidosis.

backgroundCardiac transthyretin amyloidosis (ATTR-CM) is an infiltrative, restrictive cardiomyopathy leading to heart failure across all stages of the disease. While specific disease-modulating therapies evolve, interventional therapeutic approaches on atrioventricular valve dysfunction have not yet been investigated in this cardiomyopathy and remain subject to personalized strategy. CASE SUMMARY: We present 2 patients with wild-type ATTR-CM who underwent successful transcatheter tricuspid valve edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR) 2-4 years after initial diagnosis. T-TEER was successful, and patients presented with a considerable improvement of their functional status. DISCUSSION: T-TEER represents an important therapeutic strategy for patients with TR and ATTR-CM, in whom treatment options for symptomatic improvement are scarce. TAKE-HOME MESSAGES: T-TEER might be considered in patients with TR and restrictive cardiomyopathy, such as ATTR-CM in its advanced stages. Short-term outcomes demonstrate a considerable improvement of functional capacity on top of optimal medical therapy for ATTR-CM.